丸激素对内皮功能的影响因GnRH激动剂治疗而有所不同
Natalie J Nokoff1, Lyndsey DuBose2, Samantha Bothwell1
1Division of Endocrinology, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Journal of the Endocrine Society
|June 2, 2025
概括
变性青少年的丸激素治疗影响内皮功能,对心血管健康至关重要. 淋巴激素释放激素激动剂 (GnRHa) 调节了这些效应,功能在12个月后恢复正常.
科学领域:
- 心血管科学 心血管科学
- 内分泌学 在内分泌学.
- 青少年健康 青少年健康
背景情况:
- 在跨性别成年人中,丸激素治疗与内皮功能受损有关,而内皮功能受损是心血管疾病的前体.
- 丸激素的特定影响,带有或没有性腺激素释放激素激动剂 (GnRHa),对跨性别青少年的内皮功能仍然不清楚.
研究的目的:
- 评估丸激素治疗对跨性别青少年内皮功能12个月的影响.
- 为了确定GnRHa的使用是否影响丸激素对本人群内皮功能的影响.
主要方法:
- 一项纵向的观察性研究,涉及19名跨性别青少年 (出生时分配的女性性别).
- 在基线,1个月和12个月使用臂动脉流介导扩张 (FMD) 测量了内皮功能.
- 参与者接受了临床处方的丸激素,子组接受GnRHa或不接受.
主要成果:
- 在基线和1个月,接受GnRHa的青少年的口和口病明显低于未接受GnRHa的青少年.
- 经过12个月的丸激素治疗后,GnRHa暴露和非暴露组之间的口炎水平变得相似.
- 一个显著的相互作用显示,口病在12个月内在GnRHa+组增加,在GnRHa-组减少.
结论:
- 接受GnRHa治疗的跨性别青少年在丸激素治疗之前具有较低的基线内皮功能.
- 激素对跨性别青少年内皮功能的影响受到同时使用GnRHa的影响.
- 在12个月的丸激素治疗后,内皮功能在不同组之间正常化,这表明GnRHa的调节作用.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
519
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
519
01:16Antianginal Drugs: Nitrates and β-Blockers
1.8K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.8K
01:28Nitric Oxide Signaling Pathway
6.5K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.5K
01:23Antihypertensive Drugs: Vasodilators
2.4K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.4K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
564
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
564
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
671
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
671